Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depsipeptide in Relapsed or Refractory Mantle Cell or Diffuse Large Cell Non-Hodgkin's Lymphoma
NCT00077194Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2004
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romidepsin in non-Hodgkin lymphoma (NHL), sponsored by National Cancer Institute. Primary endpoints: Objective Response Rate up to 5 years and Adverse Events up to 5 years. Started Jan 2004; status: completed.
02
Drugs
romidepsin
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00077194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00077194.